Movatterモバイル変換

[0]ホーム
URL:

IN2014DN09571A - - Google Patents

Download PDF

Info

Publication number
IN2014DN09571A
IN2014DN09571AIN9571DEN2014AIN2014DN09571AIN 2014DN09571 AIN2014DN09571 AIN 2014DN09571AIN 9571DEN2014 AIN9571DEN2014 AIN 9571DEN2014AIN 2014DN09571 AIN2014DN09571 AIN 2014DN09571A
Authority
IN
India
Prior art keywords
agonist
active ingredients
pharmaceutical formulation
special
constituent
Prior art date
Application number
Inventor
John Bondo Hansen
Mikael S Thomsen
Jens D Mikkelsen
Peter Gudmund Nielsen
Mads Kreilgaard
Original Assignee
Contera Pharma Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2012/050190external-prioritypatent/WO2012163365A1/en
Application filed by Contera Pharma ApsfiledCriticalContera Pharma Aps
Publication of IN2014DN09571ApublicationCriticalpatent/IN2014DN09571A/en

Links

Classifications

Landscapes

Abstract

The present invention provides a pharmaceutical formulation for oral administration comprising an agonist of two or more of the 5- HT1B , 5- HT1D and 5- HT1F receptors, such as a triptan , e.g. zolmitriptan , in a matrix constituent with extended release characteristics , and further comprising a 5 -HT1A- R agonist , such as buspirone , in a constituent with immediate release characteristics. The special formulation is particularly well -suited for use in the treatment of movement disorders by combining the two active ingredients in a manner that achieves synergy from both the combination per se and the special release parameters of the pharmaceutical formulation , allowing for ease of administration and reducing the risk of adverse effects of each of the two active ingredients.
IN9571DEN20142012-04-182013-04-18IN2014DN09571A (en)

Applications Claiming Priority (4)

Application NumberPriority DateFiling DateTitle
DKPA2012701962012-04-18
PCT/DK2012/050190WO2012163365A1 (en)2011-06-012012-06-01Combinations of serotonin receptor agonists for treatment of movement disorders
DKPA2012707552012-12-04
PCT/DK2013/050111WO2013156035A1 (en)2012-04-182013-04-18Orally available pharmaceutical formulation suitable for improved management of movement disorders

Publications (1)

Publication NumberPublication Date
IN2014DN09571Atrue IN2014DN09571A (en)2015-07-17

Family

ID=49382938

Family Applications (1)

Application NumberTitlePriority DateFiling Date
IN9571DEN2014IN2014DN09571A (en)2012-04-182013-04-18

Country Status (23)

CountryLink
US (1)US10561618B2 (en)
EP (1)EP2838517B1 (en)
JP (1)JP6216768B2 (en)
KR (1)KR102104635B1 (en)
CN (1)CN104411301B (en)
AU (1)AU2013248685B2 (en)
BR (1)BR112014025907B1 (en)
CA (1)CA2870123C (en)
DK (1)DK2838517T3 (en)
ES (1)ES2654787T3 (en)
HU (1)HUE037732T2 (en)
IL (1)IL235000B (en)
IN (1)IN2014DN09571A (en)
MX (1)MX361372B (en)
MY (1)MY169068A (en)
NO (1)NO2838517T3 (en)
NZ (1)NZ700474A (en)
PH (1)PH12014502331B1 (en)
PL (1)PL2838517T3 (en)
PT (1)PT2838517T (en)
RU (1)RU2670272C2 (en)
SG (1)SG11201406690SA (en)
WO (1)WO2013156035A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EP3160464B1 (en)2014-06-262018-07-18Contera Pharma APS6-hydroxybuspirone for use in the treatment of movement disorders
CA2946829C (en)2014-07-092018-05-22Pierre Fabre MedicamentA method for treating movement disorders with befiradol
CN107428745A (en)2015-01-202017-12-01Xoc制药股份有限公司Ergoline compound and application thereof
WO2018223065A1 (en)2017-06-012018-12-06Xoc Pharmaceuticals, Inc.Ergoline derivatives for use in medicine
US11135379B2 (en)2019-02-152021-10-05Bn Intellectual Properties, Inc.Method of delivering pharmaceutical products
US10758535B1 (en)2019-04-262020-09-01Sumitomo Dainippon Pharma Co., Ltd.Therapeutic drug for dyskinesia
US11559525B2 (en)2019-04-262023-01-24Sumitomo Pharma Co., Ltd.Therapeutic drug for dyskinesia
US11364225B2 (en)*2019-08-212022-06-21Bn Intellectual Properties, Inc.Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
WO2022045336A1 (en)2020-08-312022-03-03大日本住友製薬株式会社Therapeutic agent for motor complications in parkinson's disease
JP2024512069A (en)*2021-03-252024-03-18マップライト セラピューティクス，インコーポレイテッド Pharmaceutical compositions containing zolmitriptan
CN118308475B (en)*2024-03-182024-11-26安徽医科大学第一附属医院 Application of HTR1B as a diagnostic marker and therapeutic target for embryonic developmental arrest

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
BE759371A (en)1969-11-241971-05-24Bristol Myers Co HETEROCYCLICAL AZASPIRODECANEDIONES AND METHODS FOR THEIR PREPARATION
US3976776A (en)1972-12-061976-08-24Mead Johnson & CompanyTranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4166452A (en)1976-05-031979-09-04Generales Constantine D J JrApparatus for testing human responses to stimuli
US4182763A (en)1978-05-221980-01-08Mead Johnson & CompanyBuspirone anti-anxiety method
US4356108A (en)1979-12-201982-10-26The Mead CorporationEncapsulation process
US4265874A (en)1980-04-251981-05-05Alza CorporationMethod of delivering drug with aid of effervescent activity generated in environment of use
US4438119A (en)1982-12-231984-03-20Mead Johnson & CompanyMethod for alleviation of extrapyramidal motor disorders
US4640921A (en)1986-02-041987-02-03Bristol-MyersTreatment of sexual dysfunction with buspirone
US4687772A (en)1986-10-071987-08-18Bristol-Myers CompanyMethod for improvement of short term memory
US4777173A (en)1987-03-251988-10-11Bristol-Myers CompanyMethod for treatment of alcohol abuse
US5185329A (en)1988-08-301993-02-09Bristol-Myers Squibb CompanyMethod for treatment of substance addiction
US6432956B1 (en)1990-02-122002-08-13William C. DementMethod for treatment of sleep apneas
DK0486666T3 (en)1990-06-071998-03-30Zeneca Ltd Therapeutic heterocyclic compounds
US5633009A (en)1990-11-281997-05-27Sano CorporationTransdermal administration of azapirones
US5431922A (en)1991-03-051995-07-11Bristol-Myers Squibb CompanyMethod for administration of buspirone
DE4122217C2 (en)*1991-07-041997-02-13Merz & Co Gmbh & Co Process for the preparation of mechanically stable, well decomposing compressed products from small active substance-containing moldings
GB9209882D0 (en)1992-05-071992-06-24Glaxo Lab SaCompositions
US5484788A (en)1993-03-261996-01-16Beth Israel Hospital AssociationBuspirone as a systemic immunosuppressant
US5637314A (en)1995-06-071997-06-10Beth Israel Deaconess Medical Center, Inc.Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
GB9816556D0 (en)*1998-07-301998-09-30Pfizer LtdTherapy
US6150365A (en)1999-08-052000-11-21Bristol-Myers Squibb CompanyAnxiety method
GB9928578D0 (en)1999-12-032000-02-02Zeneca LtdPharmaceutical formulations
ES2292636T3 (en)2000-11-292008-03-16Eli Lilly And Company 1- (2-M-METHANOSULPHANOMIDOFENILETIL) -4- (M-TRIFLUOROMETILFENIL) PIPER.
AU2002241565A1 (en)2001-01-052002-07-16Eli Lilly And CompanyExcitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
US8329734B2 (en)2009-07-272012-12-11Afgin Pharma LlcTopical therapy for migraine
KR20040018394A (en)*2001-07-042004-03-03썬 파마슈티컬 인더스트리스 리미티드Gastric retention controlled drug delivery system
WO2003024960A1 (en)*2001-09-192003-03-27Merck Patent GmbhNovel use of substituted aminomethyl chromans
BRPI0415121A (en)*2003-10-102006-11-28Lifecycle Pharma As particulate material, solid dosage form, method of manufacturing it, and use of a particulate material or solid dosage form
US7470435B2 (en)*2003-11-172008-12-30Andrx Pharmaceuticals, LlcExtended release venlafaxine formulation
DE10353657A1 (en)2003-11-172005-06-23Merck Patent GmbhNew quinolonyl- or benzopyranonyl-substituted indole derivatives are 5HT(1A)- and/or 5HT(1D)-agonists useful e.g. as anxiolytic, antidepressant, neuroleptic and/or antihypertensive agents
US20070173536A1 (en)2004-02-062007-07-26Ciba Specialty Chemicals Holding Inc.Crystalline forms of zolmitriptan
AU2005269981A1 (en)*2004-07-022006-02-09Bonck, John ATablet for pulsed delivery
CA2578990A1 (en)*2004-09-072006-03-16Pfizer Inc.Combination of a 5-ht(1) receptor agonist and an alpha-2-delta ligand for the treatment of migraine
CA2590802A1 (en)*2004-12-202006-06-29Collegium Pharmaceutical, Inc.Pharmaceutical compositions for sleep disorders
US7632832B2 (en)*2005-01-182009-12-15Merck & Co., Inc.CGRP receptor antagonists
MX2007012374A (en)*2005-04-062008-02-22Adamas Pharmaceuticals IncMethods and compositions for treatment of cns disorders.
US20080166407A1 (en)*2005-07-292008-07-10Shalaby Shalaby WSolid oral formulations for combination therapy
US9066903B2 (en)2006-02-282015-06-30The United States Of America As Represented By The Department Of Veterans AffairsPharmacological treatment of Parkinson's disease
WO2007129329A2 (en)*2006-05-082007-11-15Jubilant Organosys LimitedExtended release pharmaceutical formulation comprising venlafaxine hydrochloride
JP2009536667A (en)*2006-05-092009-10-15ブレインセルス，インコーポレイティド 5HT receptor-mediated neurogenesis
KR20090033871A (en)*2006-06-162009-04-06솔베이 파마슈티칼스 비. 브이 Combination Formulations Containing Bifeprunox and L-DOOPA
US20080069874A1 (en)*2006-09-152008-03-20Auriga Laboratories, Inc.Kits for Prevention and Treatment of Rhinitis
WO2008047839A1 (en)*2006-10-192008-04-24Dainippon Sumitomo Pharma Co., Ltd.5-ht1a receptor agonist
JP5269894B2 (en)2007-06-272013-08-21ハンミ ファーム． シーオー．， エルティーディー． Method for producing fast-dissolving preparation for oral administration, its production, and packaging device
EP2105130A1 (en)2008-03-252009-09-30Ratiopharm GmbHPharmaceutical formula and method for its production
US20110183995A1 (en)2008-06-242011-07-28Neurosearch A/SEltoprazine for suppression of l-dopa induced dyskinesias
BRPI0920216A2 (en)2008-10-142019-09-24Mcneil Ab multiple-dose intraoral dosage form and use thereof
GEP20146013B (en)2009-01-232014-01-27Aziende Chimiche Riunite Angelini Francesco A C R A F S P A ItControlled release pharmaceutical or food formulation and method of preparation thereof
US8710092B2 (en)2009-12-232014-04-29Map Pharmaceuticals, Inc.Substituted indolo 4,3 FG quinolines useful for treating migraine
SI2627328T1 (en)*2010-10-152017-01-31Contera Pharma ApsCombinations of serotonin receptor agonists for treatment of movement disorders
EP2714040A1 (en)*2011-06-012014-04-09Concit Pharma ApSCombinations of serotonin receptor agonists for treatment of movement disorders

Also Published As

Publication numberPublication date
JP6216768B2 (en)2017-10-18
KR102104635B1 (en)2020-04-27
BR112014025907B1 (en)2023-02-14
AU2013248685B2 (en)2017-07-27
DK2838517T3 (en)2018-01-15
PH12014502331A1 (en)2014-12-22
SG11201406690SA (en)2014-11-27
CA2870123C (en)2021-02-23
PT2838517T (en)2018-01-04
RU2014145944A (en)2016-06-10
MX2014012408A (en)2014-12-10
RU2670272C2 (en)2018-10-22
BR112014025907A2 (en)2017-06-20
EP2838517A1 (en)2015-02-25
HK1207285A1 (en)2016-01-29
KR20140146207A (en)2014-12-24
ES2654787T3 (en)2018-02-15
MY169068A (en)2019-02-12
PL2838517T3 (en)2018-03-30
CN104411301A (en)2015-03-11
PH12014502331B1 (en)2019-08-23
HUE037732T2 (en)2018-09-28
WO2013156035A1 (en)2013-10-24
CN104411301B (en)2018-02-06
CA2870123A1 (en)2013-10-24
AU2013248685A1 (en)2014-10-16
IL235000B (en)2018-01-31
NO2838517T3 (en)2018-03-17
US10561618B2 (en)2020-02-18
NZ700474A (en)2016-10-28
MX361372B (en)2018-12-05
EP2838517B1 (en)2017-10-18
JP2015514727A (en)2015-05-21
US20150104506A1 (en)2015-04-16

Similar Documents

PublicationPublication DateTitle
IN2014DN09571A (en)
PH12015501595A1 (en)Spiro-lactam nmda receptor modulators and uses thereof
PH12015501598A1 (en)Spiro-lactam nmda receptor modulators and uses thereof
MX2016010213A (en)Novel pharmaceutical formulations.
PH12019501937A1 (en)Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan
PH12015501600A1 (en)Spiro-lactam nmda receptor modulators and uses thereof
MY188450A (en)Spiro-lactam nmda receptor modulators and uses thereof
UA98839C2 (en)N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
SG10201810985XA (en)Tofacitinib oral sustained release dosage forms
AR084932A1 (en) OPHTHALMIC COMPOSITION INCLUDING AN ANDROGEN AND ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF AN EYE DISEASE RESULTING FROM AN ANDROGENIC DEFICIENCY
EA201691242A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING AZD9291
MX2015009772A (en)Spiro-lactam nmda receptor modulators and uses thereof.
MA32568B1 (en) Pharmaceutical preparations containing dopamine receptor bonds
TN2015000244A1 (en)Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EE05760B1 (en) Pharmaceutical composition
EA201590805A1 (en) COMPOSITION WITH IMMEDIATE AND PROLONGED DELIVERY
PH12017501424A1 (en)Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EA201792595A1 (en) CONTRACEPTIVE MEANS BASED ON DROSPYRENON FOR A PATIENT SUFFERING AN EXCESSIVE BODY MASS
UA110979C2 (en)Liquid pharmaceutical formulation comprising nitisinone
JOP20220160A1 (en)Compounds active towards nuclear receptors
EA201300857A1 (en) PYRAZOLES AS AN ANTAGONISTS CRTH2
PH12017501736B1 (en)Indole derivatives
EA201500446A1 (en) PHARMACEUTICAL COMPOSITION TO REDUCE N-OXIDE TRIMETYLAMINE LEVEL
JP2015520154A5 (en)
TN2013000429A1 (en)Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
[8]ページ先頭
©2009-2025 Movatter.jp